ophthalmology

Samsung Bioepis and Biogen Announce EMA Filling Acceptance of SB11 (biosimilar, Lucentis)

  • by

Shots: EMA has accepted to review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). If approved, SB11 will join a growing number of biosimilars developed by Samsung Bioepis and commercialized by Biogen In Nov 2019, Samsung Bioepis announced that it entered… Read More »Samsung Bioepis and Biogen Announce EMA Filling Acceptance of SB11 (biosimilar, Lucentis)

Dealing with a Rare Eye Disease in the Midst of COVID19

  • by

Dealing with a Rare Eye Disease in the Midst of COVID19 After being diagnosed with a rare eye disease, a doctor learns the best treatment is immunosuppression-a risky choice in the midst of COVID19 The Doctor Weighs In